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Background: US military Veterans returned from Operation Enduring
Freedom/Operation Iraqi Freedom/Operation NewDawn (OEF/OIF/OND) with symptoms
associated with mild traumatic brain injury [mTBI; i.e., persistent post-concussive (PPC)
symptoms] and posttraumatic stress disorder (PTSD). Interventions aimed at addressing
symptoms associated with both physical and psychological stressors (e.g., PPC and
PTSD symptoms) are needed. This study was conducted to assess the feasibility,
acceptability, and safety of a probiotic intervention, as well as to begin the process of
evaluating potential biological outcomes.
Methods: A pilot randomized controlled trial was implemented among US military
Veterans from recent conflicts in Iraq and Afghanistan. Those enrolled had clinically
significant PPC and PTSD symptoms. Participants were randomized to intervention
(Lactobacillus reuteri DSM 17938) or placebo supplementation (daily for 8 weeks
+/- 2 weeks) at a 1:1 ratio, stratified by irritable bowel syndrome status. Thirty-one
Veterans were enrolled and randomized (15 to the placebo condition and 16 to the
probiotic condition).
Results: Thresholds for feasibility, acceptability, and safety were met. Probiotic
supplementation resulted in a decrease in plasma C-reactive protein (CRP)
concentrations relative to the placebo group that approached statistical significance
(p = 0.056). Although during the Trier Social Stress Test (TSST; administered post-
supplementation) no between-group differences were found on a subjective measure of
stress responsivity (Visual Analog Scale), there was a significantly larger increase in mean
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heart beats per minute between baseline and the math task for the placebo group
as compared with the probiotic group (estimated mean change, probiotic 5.3 [95%
Confidence Interval: −0.55, 11.0], placebo 16.9 [11.0, 22.7], p = 0.006).
Conclusions: Findings from this trial support the feasibility, acceptability, and safety of
supplementation with an anti-inflammatory/immunoregulatory probiotic, L. reuteri DSM
17938, among Veterans with PPC and PTSD symptoms. Moreover, results suggest that
CRP may be a viable inflammatory marker of interest. A larger randomized controlled trial
aimed at measuring both biological and clinical outcomes is indicated.
Clinical Trial Registration: ClinicalTrials.gov, identifier NCT02723344.
Keywords: traumatic brain injury, posttraumatic stress disorder (PTSD), probiotic, Veteran, gut-brain axis,
Lactobacillus reuteri DSM 17938, microbiome
INTRODUCTION
Many US Service Members who returned from Iraq and
Afghanistan did so with co-occurring physical and mental health
conditions, including mild traumatic brain injury (mTBI) and
posttraumatic stress disorder (PTSD). It has been estimated that
∼11–23% of those who served in Iraq or Afghanistan have
a history of mTBI, with around 8% reporting persistent post-
concussive (PPC) symptoms [e.g., sleep (insomnia), cognitive
(memory loss, poor concentration, and problem solving); (1),
emotional (depressed mood, irritability, and anxiety), and
physical (headache, dizziness, exercise intolerance, fatigue, noise,
and light sensitivity symptoms); (2)]. Among those with a history
of mTBI and PPC symptoms, co-occurring psychiatric disorders
(e.g., PTSD and depression) are common. According to work by
Bahraini et al. (3) among military and Veteran samples with a
history of TBI, “estimates of PTSD range from 12 to 89%” (p.
58). As such, there is ongoing discussion regarding the etiology of
the non-specific symptoms associated with PPC syndrome, with
a particular focus on whether such symptoms are more likely to
be associated with physical (TBI) or psychological (PTSD) injury.
For further discussion of the complicated relationship between
TBI and PTSD, see Loignon et al. (4).
Despite their frequent co-occurrence, there is a dearth
of evidence-based treatments that address symptoms of both
conditions (3, 5). According to Hoge and Jonas “[t]he critical
gap in clinical interventions will begin to get filled only when
clinicians and researchers turn their attention to developing and
validating interventions that respect the inherent non-specific
multietiological nature of these symptoms. . . ” (E2) (3, 5, 6). In
addition, persistent symptoms associated with mTBI and PTSD
are often resistant to traditional medical interventions (7). As
such, “complementary and alternative medicine (CAM) may
be sought by the patient. . . ” [p. 116; (7)]. Over the past two
decades, the use of CAM in the USA has seen a steady and
steep rise (8–10). Findings from Betthauser et al. suggest that
Veterans are open to, or are already using, CAM approaches (11).
Interestingly, results also suggest that Veterans with symptoms
associated with mTBI or PTSD may be more accepting of CAM
approaches than those without these conditions (11).
Identification of interventions aimed at symptoms associated
with both conditions would require addressing a common
mechanism. Excessive neurologic and systemic inflammation has
been found to play a role in the vulnerability to, and aggravation
and perpetuation of, adverse consequences associated with both
physical and psychological stressors (12–16). Following acute
TBI in humans, cerebral inflammatory responses begin within
minutes and include elevations of interleukin (IL)-1β, IL-6,
IL-8, and tumor necrosis factor alpha (TNFα) (15). Post-
injury (mild, moderate, and severe TBI) increases in cerebral
inflammatory responses, including microglial and astroglial
activation, can be prolonged, lasting months to years (15–
17). For example, Johnson et al. found that neuroinflammatory
processes in the corpus callosum can persist for many years
after a single moderate-to-severe TBI (17). Among military
personnel who sustained mTBIs during their last deployment,
those with mTBI plus loss of consciousness had significantly
elevated IL-6 concentrations compared to those with mTBI and
no loss of consciousness or no history of TBI (16). Moreover,
within both mTBI groups, increased TNFα was associated with
greater PTSD symptoms (16). The influence of inflammatory
responses on evolving symptomatology and pathology (17)
underscores inflammation as a potential target for treatment,
long after the acute physical or psychological trauma has taken
place (13, 14, 16).
In prospective studies, high baseline plasma concentrations of
the inflammatory marker, C-reactive protein (CRP), measured
pre-deployment among military personnel, were associated
with the increased likelihood of having PTSD symptoms post-
deployment, thereby suggesting that inflammation prior to
trauma exposure may predispose individuals to developing
PTSD (18). Similarly, elevated inflammation within hours
of a traumatic event may predict adverse psychological and
neurological outcomes. For example, increased circulating levels
of IL-6 are associated with increased trauma exposure and
associated diagnoses [i.e., PTSD; (19)]. These clinical findings
are supported by rodent studies demonstrating a causal role
for elevated baseline IL-6 in vulnerability to an anxiety- and
depression-like syndrome (20).
As noted above, pre-existing inflammation, as well as
associated background immunodysregulation, are risk factors
for the development of PPC and PTSD symptoms (15, 18).
Pretreatment with an immunoregulation-inducing agent may be
expected to attenuate development and persistence of symptoms.
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Bio-immunomodulatory probiotics, such as Lactobacillus reuteri
DSM 17938, have the potential to decrease stress-induced
inflammatory responses, while being highly accessible, low cost,
self-sustaining (e.g., portable), and, based on previous safety
and tolerability trials, without serious side effects. Due to their
proven ability to bind to the pattern recognition receptor
dendritic cell-specific intercellular adhesionmolecule-3-grabbing
non-integrin (DC-SIGN), to induce proliferation of regulatory
T cells (Treg), and to increase production of anti-inflammatory
cytokines, including IL-10 and transforming growth factor
β (TGFβ), probiotics are logical candidates for treatment of
co-occurring PPC and PTSD symptoms (21). Moreover, in
pre-clinical models, administration of the immunoregulatory
probiotic DSM 17938, L. reuteri, has been found to promote
homeostasis in the gut microbiota (22, 23), alleviating dysbiosis
and enhancing eradication of proinflammatory pathobionts,
including Helicobacter species (22–26). L. reuteri has also been
found to assist in restoring the intestinal mucosal barrier by
increasing enterocyte migration, proliferation, and crypt height
(22, 23, 27). Of note, restoration of the mucosal barrier reduces
bacterial translocation to mesenteric lymph nodes, thereby
further reducing systemic inflammation.
The following pilot trial of an immunomodulatory probiotic
supplementation, L. reuteri DSM 17938, was implemented
among Veterans from Operation Enduring Freedom/Operation
Iraqi Freedom/Operation New Dawn (OEF/OIF/OND) with
co-occurring PPC and PTSD symptoms using a longitudinal,
double-blind, randomized placebo-controlled design. Study aims
included evaluating the feasibility, acceptability, and safety of
supplementation. Feasibility refers to the ease of implementation,
and acceptability refers to the suitability of an intervention
from the perspectives of the stakeholders [e.g., participants, and
providers; (28)]. In addition, efforts were aimed at evaluating the
impact of supplementation on biological markers (i.e., systemic
inflammation, intestinal permeability, stress responsivity, and
microbial diversity and composition).
MATERIALS AND METHODS
Participants
This study was approved by the Colorado Multiple Institutional
Review Board (IRB) and the local VA Research and Development
Committee. Written informed consent was provided in
accordance with the Declaration of Helsinki. Participants
included US military Veterans between the ages of 18 and 50
with (1) at least one deployment in support of OEF/OIF/OND;
(2) a history of mTBI per the Ohio State University (OSU)
TBI-ID (29) with any endorsement of PPC symptoms associated
with an mTBI that occurred at least 6 months prior to the
baseline assessment; (3) current symptoms in three or more of
the following International Classification of Diseases (ICD)-10
post-concussive (PC) symptom categories (30) as measured
by the Rivermead Post-concussion Symptom Questionnaire
[RPQ; score of 2 or greater per symptom to qualify as (a)
headache, dizziness, malaise, fatigue, and noise intolerance;
(b) irritability, depression, anxiety, and emotional lability; (c)
subjective concentration, memory, or intellectual difficulties;
and/or (d) insomnia] (31); (4) a current diagnosis of PTSD per
the Clinician Administered PTSD Scale-5 (CAPS-5) (32); and
(5) medical clearance by study providers. Exclusion criteria
included: (1) history of moderate-to-severe TBI; (2) current
involvement in the criminal justice system as a prisoner or
ward of the state; (3) current (past month) alcohol or substance
abuse or dependence; (4) lifetime history of bipolar disorder
or psychosis or anxiety disorders; (5) consistent (e.g., 5×/week
or greater) probiotic supplementation within the last month,
including probiotic food products such as yogurt, as determined
by phone screen interview and Probiotic Food Check List;
(6) receiving antibiotics within the last month; (7) receiving
medications that interfere with gut motility (opiates, loperamide,
and stool softeners); (8) presence of central venous catheters
(CVCs); (9) gastrointestinal (GI) barriers as identified by the
2-week run-in period as determined by the study team (e.g., daily
GI discomfort with frequent diarrhea prior to supplementation);
(10) participation in conflicting interventional research protocol;
(11) vital signs outside of acceptable range, i.e., blood pressure
>160/100, oral temperature >100◦F, and pulse >100; (12)
use of any drugs within the last 6 months [viz., systemic
antibiotics, antifungals, antivirals, or antiparasitics (intravenous,
intramuscular, or oral); oral, intravenous, intramuscular, nasal
or inhaled corticosteroids; cytokines or cytokine inhibitors;
methotrexate or immunosuppressive cytotoxic agents]; (13)
acute disease at the time of enrollment; (14) chronic, clinically
significant (unresolved, requiring on-goingmedical management
or medication) pulmonary, cardiovascular, GI, hepatic, or renal
functional abnormality, as determined by medical history or
physical examination other than irritable bowel syndrome
(IBS); (15) history of cancer except for squamous or basal cell
carcinomas of the skin that have been medically managed by
local excision; (16) unstable dietary history as defined by major
changes in diet during the previous month, where the subject
has eliminated or significantly increased a major food group
in the diet; (17) positive test for human immunodeficiency
virus (HIV), hepatitis B virus, or hepatitis C virus; (18) major
surgery of the GI tract, with the exception of cholecystectomy
and appendectomy, in the past 5 years or any major bowel
resection at any time; (19) regular urinary incontinence
necessitating use of incontinence protection garments; (20)
female who is pregnant or lactating; (21) treatment for or
suspicion of ever having had toxic shock syndrome; or (22)
those receiving immunosuppressive drugs/medications (e.g.,
oral corticosteroids) or treatment including antineoplastic
therapy, post-transplantation immunosuppressive therapy,
and/or radiation therapy.
Participant demographics and clinical characteristics [e.g., IBS
status as measured by the Rome III Diagnostic Questionnaire
(33) and dietary diversity] are presented in Table 1. The average
age of the male Veterans included in the study was 37.4 years (SD
6.7). The sample was 68%Caucasian. No significant demographic
or military characteristic differences were noted. In terms of
most recent and worst mTBIs (lifetime), there were no significant
between-group differences in terms of the number of participants
in each group with alterations of consciousness (AOC) vs. losses
of consciousness (LOC) [most recent: AOC—placebo 8 (53%),
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TABLE 1 | Participant demographics and clinical characteristics.
Total (N = 31) Placebo (N = 15) Probiotic (N = 16) p-value
Demographics







Maleb 31 (100%) 15 (100%) 16 (100%) >0.99
Raceb
Caucasian 21 (68%) 10 (67%) 11 (69%) 0.56
African American 2 (6%) 1 (7%) 1 (6%)
Native American/Alaskan Native 2 (6%) 2 (13%) 0 (0%)
Multiracial 4 (13%) 2 (13%) 2 (12.5%)
Other 2 (6%) 0 (0%) 2 (12.5%)
Hispanicb 3 (10%) 2 (15%) 1 (6%) 0.59
Educationb
Some college 16 (52%) 5 (33%) 11 (69%) 0.06
Associate’s 7 (23%) 5 (33%) 2 (29%)
Bachelor’s 6 (19%) 5 (33%) 1 (6%)
Master’s 1 (3%) 0 (0%) 1 (6%)
Doctoral 1 (3%) 0 (0%) 1 (6%)
Marital Statusb
Married 21 (68%) 11 (73%) 10 (48%) 0.76
Single 4 (13%) 1 (7%) 3 (19%)
Cohabitating 3 (10%) 2 (13%) 1 (6%)
Divorced/Separated 3 (10%) 1 (7%) 2 (13%)
Sexual Orientationb
Heterosexual 28 (90%) 14 (93%) 14 (88%) >0.99
Gay/Lesbian/Queer 1 (3%) 1 (7%) 0 (0%)
Bisexual 1 (3%) 0 (0%) 1 (6%)
Other 1 (3%) 0 (0%) 1 (6%)
Employmentb
Full time 18 (58%) 9 (60%) 9 (56%) >0.99
Part time 3 (10%) 1 (7%) 2 (13%)
Unemployed/Not seeking 3 (10%) 1 (7%) 2 (13%)
Unemployed/Seeking 3 (10%) 2 (13%) 1 (6%)
Retired 4 (13%) 2 (13%) 2 (13%)
Studentb
Full time 10 (32%) 6 (40%) 4 (25%) 0.15
Part time 2 (6%) 2 (13%) 0 (0%)
No 19 (61%) 7 (47%) 12 (75%)
Homelessb 0 (0%) 0 (0%) 0 (0%) >0.99
Military Branchb
Army 27 (87%) 14 (93%) 13 (81%) 0.60
Air Force 1 (3%) 0 (0%) 1 (6%) >0.99
Navy 3 (10%) 1 (7%) 2 (13%) >0.99
Marines 2 (6%) 1 (7%) 1 (6%) >0.99
Erab
Post-Vietnam 2 (6%) 1 (7%) 1 (6%) >0.99
Desert Storm 6 (19%) 2 (13%) 4 (25%) 0.65
OEF/OIF/OND 31 (100%) 15 (100%) 16 (100%) >0.99
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TABLE 1 | Continued
Total (N = 31) Placebo (N = 15) Probiotic (N = 16) p-value








Irritable Bowel Syndrome (per Rome III
Diagnostic Questionnaireb )
7 (23%) 3 (20%) 4 (25%) >0.99
Ohio State University TBI-ID














The Clinician Administered PTSD
Scale-5 (CAPS-5)a
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Total (N = 28) Placebo (N = 14) Probiotic (N = 14) p-value
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TABLE 1 | Continued
Dietary Diversity Score (DDS)a,f Total (N = 29) Placebo (N = 13) Probiotic (N = 16) p-value







aMean (SD) and Median (range).
bN (%) is presented.
cHigher PSQI scores indicate worse sleep quality.
dN = 27.
eN = 13.
fDDS is calculated as the number of foods eaten on a regular basis as a proportion of all possible foods.
gTotal DDS comprises regularly eaten foods as a proportion of 144 possible foods included on the Harvard Food Frequency Questionnaire.
hFruits and Vegetables comprises 35 possible foods, including a range of fruits and vegetables such as stone fruits, apples, berries, melons, citrus, avocado, cruciferous vegetables,
alliums, root vegetables, and tomatoes, among others.
iComplex Carbohydrates comprises 13 possible foods: oatmeal, cooked grain cereals, rye bread, dark bread, brown rice and other grains, corn, popcorn, oat bran, other bran, wheat
germ, potatoes, and sweet potatoes.
jAnimal Foods comprises 32 possible foods of animal origin, including milk, fermented dairy products, eggs, red meat, poultry, fish and seafood, and processed meat products (e.g.,
hot dogs).
kPlant Proteins comprises 9 foods that are commonly consumed as plant-based sources of protein: tofu, string beans, peas and lentils, beans, peanuts and peanut butter, walnuts,
other tree nuts, and soy milk.
probiotic 13 (81%), LOC—7 (47%), 3 (19%), p= 0.14; worst:
AOC—placebo 4 (27%), probiotic 9 (56%), LOC—placebo 11
(73%), probiotic 7 (44%), p = 0.10]. There were also no between
group differences in terms of reported specific lengths of LOC
(most recent/worst mTBI) reported among those with such a loss
(p = 0.53, p = 0.38). Though not significant, 69% of those in the
probiotic group had “some college” compared with 33% in the
placebo group. No significant differences were noted on clinical
interviews/participant reported outcomes at baseline regarding
PPC symptoms, PTSD symptoms, sleep, or diet.
Randomization
Processes were in place to randomize to intervention or placebo
at a 1:1 ratio, stratified by gender and IBS, as measured by the
Rome III Diagnostic Questionnaire (33). Despite efforts to recruit
both women and men, no female Veterans met inclusion criteria.
The decision to stratify by IBS was related to the findings by
Maguen et al. (34) regarding the association between GI disorders
(GIDs) and mental health conditions among OEF/OIF Veterans.
Moreover, in conceptualizing PTSD as a more holistic disorder,
there was concern that those with IBS may be more responsive to
a probiotic intervention than those without GIDs.
Study Procedures
Study data were acquired over multiple timepoints (see
Figure 1, CONSORT diagram). Fecal microbiome samples were
collected pre- (Time 2, Assessment and Randomization) and
post-supplementation (Time 3, Assessment) by self-sampling.
Participants were provided with kits that included one BBL R©
CultureSwab R© EZ Sterile double-tipped swab (BD, Franklin
Lakes, NJ, USA), a sealable tube, and one pair of latex gloves to
collect a stool sample. Blood samples were collected pre- (Time
2, Assessment and Randomization) and post-supplementation
(Time 3, Assessment) for quantification of plasma concentrations
of biomarkers of inflammation and gut permeability. The Trier
Social Stress Test (TSST) was administered during the Time
3 Assessment.
Intervention
All participants were randomized to receive either L. reuteri
DSM 17938 drops, 100 million colony-forming units (CFU)
in sunflower and medium chain triglyceride oils or placebo
(sunflower and medium chain triglyceride oils) daily for 8 ±
2 weeks. L. reuteri DSM 17938 [deposited in the Deutsche
Sammlung vonMikroorganismen und Zellkulturen (DSMZ) and
referenced as DSM 17938; Gerber Soothe Colic Drops, 100
million CFU/5 drops; derived from L. reuteri American Type
Culture Collection (ATCC) 55730] was used in the study.
Measures
Baseline Demographics and Mental/Physical Health
Characteristics
Multiple measures were used to assess participants’ baseline
mental and physical health. The CAPS-5 is a gold-standard
structured clinical interview used to determine PTSD diagnosis
(32). The Neurobehavioral Symptom Inventory (NSI) is a
measure of PPC symptoms that is widely used among military
personnel and Veterans and is recommended for screening
and evaluation (35). Finally, the OSU-TBI-ID is a structured
clinical interview to assess for history of TBI (29). Additional
baseline clinical information was collected from each participant.
The Harvard Food Frequency Questionnaire (FFQ) booklet is
a comprehensive 101-item semi-quantitative FFQ that includes
questions on the intake of specific foods and supplements and
on adherence to particular diet types (36). Analysis of the
questionnaire provides a wide range ofmacro- andmicronutrient
quantities. The Pittsburgh Sleep Quality Index (PSQI) was used
to measure a range of factors associated with sleep (e.g., duration,
frequency of disturbances, and overall sleep quality) (37, 38).
The Rome III Diagnostic Questionnaire for the Adult Functional
Gastrointestinal Disorders classifies disorders of the digestive
system (33). This comprehensive questionnaire takes 20–30min
to complete and has been used to identify inclusion criteria for
clinical research studies (33).
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FIGURE 1 | CONSORT diagram depicting the study design.
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Feasibility and Acceptability
Participants were provided with a probiotics usage log, one
of several assessment measures linked to feasibility (28). The
participants documented the date, time, and amount of each
probiotic dose taken, as well as any symptoms experienced and
their severity. The document was modeled after the Dana-Farber
Harvard Cancer Center (DF/HCC) Oral Chemotherapy Drug
Diary. In addition, section G of the Adult AIDS Clinical Trials
Group (AACTG) (39) is a 14-item self-report questionnaire
administered to query why one might not take a supplement
as directed. The Generic Assessment of Side Effects (GASE)—
Probiotics (GASE-P) is identical to GASE but assesses side
effects related to supplements (40). The GASE consists of
36 symptom descriptions organized by parts of the body.
Participants were asked to rate if these “symptoms” were “not
present,” “mild,” “moderate,” or “severe” in the past week related
to current medication. The Modified Morisky Medication-
Taking Adherence Scale (MMAS) is an eight-item self-report
questionnaire designed to test whether or not a subject adheres
to taking a particular medication or supplement and has
demonstrated concurrent and predictive validity, in regard
to the measurement of patient adherence in clinical studies
(41, 42). If a participant scores higher on the scale, they are
more adherent to the supplement. The Modified Treatment
Satisfaction Questionnaire (TSQM v1.4) is a nine-item valid
questionnaire that is designed to measure side effects associated
with the supplement itself and the ease of administration of the
supplement (43). Participant retention and adverse event records
were maintained by study staff.
Biomarkers of Inflammation
Converging lines of evidence have shown that inflammation
is associated with mTBI and the development of PTSD (12–
16). Therefore, we measured multiple systemic biomarkers of
inflammation from plasma. These consisted of CRP, measured
by high-sensitivity enzyme-linked immunosorbent assay (ELISA)
(Cat No. DCRP00, R&D Systems, Minneapolis, MN, USA), and a
panel of cytokines [IL-1α, IL-1β, IL-2, IL-6, IL-8, IL-10, IL-12p70,
TNFα (active trimer), and interferon gamma (IFNγ)] measured
by high-sensitivitymultiplex ELISA (Cat No. 85-0002, Quanterix,
Billerica, MA, USA).
Intestinal Permeability
Biomarkers of intestinal permeability consisted of intestinal fatty
acid binding protein (IFABP) (Cat No. DFBP20, R&D Systems)
and D-amino acid oxidase (DAO) (Cat No. SEJ298Hu, Cloud
Clone, Katy, TX, USA) measured by ELISA. All assays were run
according to the manufacturer’s instruction manuals.
Stress Responsivity
To evaluate stress responsivity, the TSST (44, 45) was
administered. The TSST is a standard laboratory assessment
that has been used in a variety of populations, including
military personnel and individuals with mental health conditions
(46). With the use of a remote heart rate monitor placed
around the base of the sternum, heart beats per minutes
(BPM) was continuously measured during the TSST. Signals
were recorded with an ADInstruments system. Timepoints of
interest for BPM were at baseline (20-min relaxation), pre-
speech, during the speech, during the math task, and after a
period of relaxation (10-min post-relaxation). In the speech task,
participants are asked to give a 5-min presentation on why
they are the best candidate for a job. During the presentation,
evaluators maintain neutral expressions. If the participant does
not present for the entire 5min, they are asked to continue
until time has expired. In the math task, participants are
asked to count backwards by 13s. If they make a mistake,
they have to start from the original number given. The Visual
Analog Scale (VAS; distress thermometer) is a psychometric
response scale for subjective characteristics or attitudes (47).
Participants responded to their subjective level of stress on a
0–10 Likert scale. The VAS was administered before the speech
task, immediately after the speech task, and immediately after the
math task.
Microbiome
Sample DNA was extracted using the PowerSoil DNA extraction
kit (Cat No. 12955-4, Qiagen, Valencia, CA, USA) according
to the manufacturer’s instructions. Marker genes in isolated
DNA were polymerase chain reaction (PCR) amplified using
GoTaq Master Mix (Cat No. M5133, Promega, Madison, WI,
USA); 515 F (5′-GTGCCAGCMGCCGCGGTAA-3′) and 806 R
(5
′
-GGACTACHVGGGTWTCTAAT-3′) primer pair (Integrated
DNA Technologies, Coralville, IA, USA) targeting the V4
hypervariable region of the 16S rRNA gene modified with a
unique 12-base sequence identifier for each sample; and the
Illumina adapter as previously described in Caporaso et al. (48)
The thermal cycling program consisted of an initial step at
94◦C for 3min followed by 35 cycles (94◦C for 45 s, 55◦C for
1min, and 72◦C for 1.5min), and a final extension at 72◦C for
10min. PCRs were run in duplicate, and the products from the
duplicate reactions were pooled and visualized on an agarose gel
to ensure successful amplification. PCR products were cleaned
and normalized using a SequalPrep Normalization Kit (Cat. No.
A1051001, ThermoFisher, Waltham, MA, USA) following the
manufacturer’s instructions. The normalized amplicon pool was
sequenced on an Illumina MiSeq run by using V3 chemistry
and 600 cycles, 2 × 300-bp paired-end sequencing. All library
preparation and sequencing were conducted at the University
of Colorado Boulder BioFrontiers Next-Gen Sequencing core
facility, https://bficores.colorado.edu/sequencing-lab.
Analyses
Baseline Demographics and Mental/Physical Health
Characteristics
Demographic and clinical characteristics were compared
between groups using Wilcoxon rank-sum and Fisher’s exact
tests, as appropriate.
Feasibility and Acceptability
Measures are reported as both means and standard deviations,
as well as medians and ranges, and were compared between
groups using Wilcoxon rank-sum tests. All analyses were run
in SAS v9.4 and R v3.5.3. In terms of feasibility, we used the
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criteria of Thabane et al. (49) who suggest classifying outcomes
as follows: “(i) Stop—main study not feasible; (ii) Continue,
but modify protocol—feasible with modifications; (iii) Continue
without modifications, but monitor closely—feasible with close
monitoring; and (iv) Continue without modifications—feasible
as is.” The a priori criterion for continuing without modifications
(feasible as is) was as follows: medium adherence with
supplementation in at least 50% of all participants on all
administrations of the MMAS and retention of 50% through at
least six such administrations.
Stress Responsivity
A mixed-effects model with a random intercept was used to
investigate heart BPM during the TSST (baseline, pre-speech,
speech, math, and post-relax), representing repeated measures
on a participant over time. Within this model, each group was
allowed to have its own trajectory, and a natural cubic B-spline
transformation was performed on the timepoints to allow for
smoothly varying trajectories. A search was performed to arrive
at the overall best model, using a range of 1–3 degrees of freedom
(df) for each group (all combinations were investigated for a
total of nine models). Akaike’s information criterion (AIC) was
used to select the final model. A contrast within the final model
was used to compare the change from baseline to math between
the groups. A similar analysis was used to investigate changes in
perceived stress (VAS), though these were collected at three TSST
timepoints; a smaller range of 1–2 df was allowed for each group,
and a total of four models were run for each outcome. AIC was
again used to select the final models. Estimates from the VAS
are reported, and the change from baseline to after math was
compared between groups for the VAS using a contrast within
the model.
Biomarkers of Inflammation and Intestinal
Permeability
Given small sample sizes, differences in 8-week changes
for plasma concentrations of CRP, plasma concentrations of
cytokines, and plasma concentrations of biomarkers of intestinal
permeability measures were compared using Wilcoxon rank-
sum tests.
Probiotic and Microbiome
Sequencing data were processed and analyzed using Quantitative
Insights Into Microbial Ecology (QIIME2 v. 2019.10) (50). The
DADA2 algorithm was used to denoise demultiplexed sequences
(51). Quality-filtered sequences were assigned taxonomic
classification based on the SILVA 132 database released on
December 2017 (52). Further analyses of α-diversity, β-diversity,
and taxonomic composition of microbiomes were performed
with QIIME2 v. 2019.10 and the open source statistical package R
v. 3.5.1 (https://www.R-project.org). For α-diversity, β-diversity,
and taxonomic composition of microbiomes, samples were
rarefied to 11,900 sequences per sample. α-Diversity metrics
included (1) observed operational taxonomic units (OTUs); (2)
Shannon diversity; and (3) Faith’s phylogenetic diversity (Faith’s
PD). Kruskal–Wallis test was used to examine for differences
among treatment group and timepoint. For β-diversity,
permutational multivariate analysis of variance (PERMANOVA)
was performed using the vegan package (53) with the following
distance metrics: unweighted UniFrac and weighted UniFrac.
Analysis of Composition of Microbiomes (ANCOM) (54) was
used to determine differentially abundant taxa at the phylum and
genus levels.
RESULTS
Overall, 75 individuals were screened, and 31 Veterans were
enrolled and randomized (15 to the placebo condition and 16 to
the probiotic condition).
Feasibility
Findings from theMMAS (range 0–8) suggested that both groups
were highly adherent across all study weeks (placebo median =
7.6; probiotic median = 7.3), thereby suggesting feasibility in
terms of supplementation adherence. This was further supported
by findings from the AACTG (39) adherence questionnaire. The
most frequent reason reported in both groups for not taking
supplementation was forgetting. Nonetheless, participants in
both groups reported “rarely” forgetting to take the supplement
(placebo mean= 0.11; probiotic mean= 0.16).
Acceptability
Based on scores from the TSQM, both groups (placebo and
probiotic) found the supplementation acceptable. No differences
were noted between groups in terms of side effects, convenience,
or global satisfaction. Time 3 global satisfaction scores were ∼70
(out of 100) for both groups, thereby suggesting the acceptability
of L. reuteri DSM 17938 supplementation for those with chronic
PPC and PTSD symptoms.
On the GASE-P, no differences were noted between groups
in terms of probiotic-specific side effects or the severity of
symptoms. Interestingly, when participants were asked to rate
if these “symptoms” were “not present,” “mild,” “moderate,” or
“severe” in the past week related to current medication, side
effects notably decreased for both groups over time (see Table 2).
In addition, no severe study-related adverse events were reported
throughout the trial.
Inflammatory Markers
Probiotic supplementation resulted in a decrease in plasma
CRP concentrations that approached statistical significance. See
Table 3 for results.
Intestinal Permeability
No differences in outcomes were noted between groups
(see Table 3).
Stress Responsivity
Both objective and subjective measures of stress were obtained.
Participants in both the placebo and supplement groups
experienced an increase in estimated perceived stress using the
VAS over the course of the TSST (estimated mean, probiotic [n
= 12]: baseline, 5.38 [95% CI: 3.85, 6.90], after speech 6.25 [95%
CI: 4.87, 7.63], after math 7.13 [95% CI: 5.60, 8.65]; placebo [n=
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TABLE 2 | Generic Assessment of Side Effects-Probiotics (GASE-P) scores by timepoint.
Full Sample Placebo Probiotic p-value
N Mean (SD) Median (range) N Mean (SD) Median (range) N Mean (SD) Median (range)
Time 1
Severity 31 26.9 (13.1) 25 (6, 48) 15 25.6 (13.9) 25 (6, 48) 16 28.1 (12.7) 25 (8, 47) 0.60
Symptom count 31 15.2 (5.9) 16 (5, 28) 15 14.4 (5.5) 16 (5, 22) 16 15.9 (6.4) 15 (5, 28) 0.65
Time 2
Severity 29 22.9 (11.1) 24 (6, 52) 15 22.1 (13.2) 24 (6, 52) 14 23.7 (8.8) 22.5 (11, 41) 0.58
Symptom count 29 13.9 (5.8) 15 (4, 24) 15 12.4 (6.4) 14 (4, 24) 14 15.6 (4.8) 15 (9, 24) 0.19
Time 3
Severity 27 12.9 (11.5) 8 (0, 39) 15 11.7 (11.3) 8 (0, 39) 12 14.3 (12.0) 12.5 (0, 33) 0.52
Symptom Count 27 8.0 (6.7) 7.0 (0, 29) 15 6.5 (4.5) 5 (0, 16) 12 9.8 (8.5) 7.5 (0, 29) 0.31
TABLE 3 | Mean change in plasma concentrations of C-reactive protein (CRP), plasma concentrations of cytokines and plasma concentrations of biomarkers of intestinal
permeability from Visit 2 to Visit 3.
Placebo Probiotic p-value
N Mean (SD) and Median (range)a N Mean (SD) and Median (range)a
Biomarkers of Inflammation
CRP (mg/L) 14 0.113 (1.2) 0.09 (−2.3, 2.4) 10 −0.625 (1.1) −0.565 (−2.3, 1.5) 0.056
IFNγ (pg/ml) 14 0.36 (1.2) 0.04 (−1.4, 3.9) 9 −0.33 (1.2) −0.04 (−3.1, 1.1) 0.22
IL1α (pg/ml) 14 0.98 (4.0) 0.28 (−4.4, 12.7) 9 −1.6 (11.2) 1.64 (−30.4, 9.6) 0.45
IL1β (pg/ml) 14 0.70 (2.7) 0.04 (−3.5, 9.1) 9 −0.25 (2.5) −0.03 (−6.1, 3.3) 0.37
IL2 (pg/ml) 14 0.02 (0.34) −0.02 (−0.60, 0.81) 9 −0.12 (1.3) 0 (−3.4, 1.3) 0.51
IL6 (pg/ml) 14 0.22 (2.4) −0.10 (−5.1, 4.0) 9 −0.07 (7.7) −0.24 (−13.5, 16.3) 0.64
IL8 (pg/ml) 14 −4.8 (11.2) −0.49 (−39.2, 3.6) 9 1.4 (5.9) 1.1 (−8.8, 11.4) 0.12
IL10 (pg/ml) 14 0.15 (0.85) 0.09 (−1.4, 2.2) 9 −0.23 (2.0) −0.23 (−3.0, 2.4) 0.72
IL12p70 (pg/ml) 14 −1.6 (9.3) −0.41 (−28.5, 11.2) 9 −10.1 (46.2) −0.61 (−129, 34.3) 0.89
IL-6:IL-10 ratio 14 −0.08 (1.0) −0.004 (−3.2, 1.6) 9 −0.003 (0.97) −0.12 (−0.7, 1.6) 0.52
TNFα (pg/ml) 14 −0.62 (1.4) −0.27 (−3.7, 1.3) 9 −2.1 (8.2) 0 (−23.7, 3.2) 0.26
Intestinal Permeability
DAO (ng/ml) 10 −0.11 (0.24) −0.08 (−0.55, 0.29) 8 0.03 (0.12) 0.08 (−0.12, 0.16) 0.17
IFABP (pg/ml) 12 −0.09 (0.45) −0.17 (−1.0, 0.72) 10 −0.04 (0.16) −0.03 (−0.35, 0.21) 0.54
aNegative numbers indicate a decrease from Visit 2 to Visit 3. Wilcoxon rank-sum test was used to compare the change from Visit 2 to Visit 3 between the Placebo and Probiotic groups.
CRP, C-reactive protein; DAO, D-amino acid oxidase; IFABP, intestinal fatty acid binding protein; IFNγ, interferon gamma; IL, interleukin; mg/L, milligrams/liter; ng/ml, nanograms/ milliliter;
pg/ml, picograms/ milliliter; TNFα, tumor necrosis factor alpha.
15]: baseline 4.13 [95% CI: 2.77, 5.50], after speech 5.29 [95% CI:
4.04, 6.54], after math 6.44 [95% CI: 5.06, 7.84]). Moreover, no
significant between-group differences were noted on estimated
changes in VAS scores from baseline to after math (estimated
change, probiotic 1.75 [95% CI: 0.49, 3.01]; placebo 2.31 [95% CI:
1.15, 3.47], p = 0.51). Nonetheless, during the TSST, there was a
significantly larger increase in mean BPM between baseline and
math for the placebo group as compared with the probiotic group
(estimated change, probiotic 5.3 [95% CI: −0.55, 11.0], placebo
16.9 [95%CI: 11.0, 22.7], p= 0.006). Of note, the groups were not
significantly different at baseline (estimated difference at baseline,
4.5 [95% CI:−7.66, 16.7], p= 0.46; see Figure 2).
Microbiome
Presence of L. reuteri DSM 17938 in the Supplement
The presence of L. reuteri DSM 17938 in the prepared
supplement was confirmed through amplification with species-
specific primers using SYBR Green master mix in a Bio-Rad
CFX qPCR machine. Positive placebo for the amplification
was measured with L. reuteri DSM 17938 DNA provided by
ATCC and compared with DNA extracted from three separate
probiotic oil samples. DNA for the positive placebo and three
samples was quantified for four dilution factors of 1, 1:10, 1:100,
and 1:1,000. Results showed that the positive placebo and all
three samples amplified at each of the four dilution factors.
All the melt curves indicated amplification of the same target
sequence, with no indication of non-specific amplification. The
highest dilution factor (1:1,000) had CT values still under 30 for
the probiotic samples. In addition, the three probiotic samples
had similar amplification in each of the four dilution factors,
indicating nearly uniform L. reuteri DSM 17938 concentrations
in the probiotic samples.
α-Diversity, β-Diversity, and Taxonomic Composition
of the Gut Microbiome
The mean α-diversity for the study population was 108.8
for observed OTUs and 3.23 for Shannon diversity. Relative
abundances of the most prevalent gut bacteria at the phylum
level were 41.2% Firmicutes, 34.9% Bacteroidetes, and 17.9%
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Proteobacteria. The mean Firmicutes to Bacteroidetes ratio
was 2.58 across the study, not significantly different across
timepoints or treatment groups. Bacteroides, Escherichia–
Shigella, Faecalibacterium, and Prevotella were the highest
FIGURE 2 | Beats per Minute (BPM) with Standard Error Bars by Trier Social
Stress Test.
relative abundance genera across all samples. Overall, there were
no differences between treatment group or timepoint in α-
diversity, β-diversity, or taxa at the phylum or genus level (see
Figures 3–6 for more details).
DISCUSSION
Findings from this trial support the feasibility,
acceptability, and safety of supplementation with an anti-
inflammatory/immunoregulatory probiotic, L. reuteri DSM
17938, among Veterans with PPC and PTSD symptoms. As
noted above, we were broadly unable to detect differences
between groups in biomarkers of inflammation (including IL-1α,
IL-1β, IL-2, IL-6, IL-8, IL-10, IL-12p70, TNFα (active trimer),
and IFNγ) or biomarkers of intestinal permeability. These
findings are consistent with a recent meta-analysis, which found
that probiotic administration among a wide-range of cohorts
(e.g., healthy, IBS, obese, and TBI) had no significant effect on
serum cytokines including IL-10 and TNFα (55).
Nonetheless, meta-analytic findings suggested that probiotic
administration resulted in a reduction in serum CRP, with a
weighted mean difference (WMD) of−1.35 mg/L [95% CI−2.15
FIGURE 3 | Relative abundances of phyla in the participant gut microbiome, before and after placebo or probiotic administration.
Frontiers in Neurology | www.frontiersin.org 11 October 2020 | Volume 11 | Article 1015
Brenner et al. Probiotic for mTBI and PTSD
FIGURE 4 | Principal coordinate plots with (A) weighted UniFrac and (B) unweighted UniFrac.
FIGURE 5 | Boxplots depicting α-diversity based on Faith’s phylogenetic
diversity measure between treatment groups before and after placebo or
probiotic administration.
to −0.55, I2 65.1% (55)]. One of the articles noted in the meta-
analysis was a randomized, single-blind study by Tan et al.
of those with severe TBI (56). Those in the probiotic group
received 0.5 × 108 Bifidobacterium longum (ATCC 15697), 0.5
× 107 Lactobacillus bulgaricus (ATCC 11842), and 0.5 × 107
Streptococcus thermophilus (ATCC 19987). CRP levels were lower
on days 15 and 21 among those who received the probiotic,
relative to those in the placebo group.
In the current study, notable between-group differences were
identified in terms of plasma concentrations of CRP, suggesting
that CRP may be a viable inflammatory marker of interest. This
may have been related to effects of L. reuteri DSM 17938 on
the gut–liver axis (i.e., physiological links among gut dysbiosis,
FIGURE 6 | Boxplots depicting α-diversity based on Shannon diversity
measure between treatment groups before and after placebo or probiotic
administration.
the integrity of the gut barrier and, via the hepatic portal
vein, the hepatic immune and acute phase responses to gut-
derived factors). This finding is also in line with previous
studies suggesting that probiotic administration can decrease
plasma CRP concentrations (55). Not all studies using L.
reuteri DSM 17938 have observed decreases in plasma CRP
concentrations, however (57, 58). Nonetheless, the potential for
L. reuteri DSM 17938 to decrease plasma CRP concentrations
may be of particular interest in the context of PTSD. In a
Marine Resiliency Study of ∼2,600 war zone-deployed soldiers,
elevated plasma CRP concentrations at baseline predicted
elevated PTSD risk 3 months post-deployment (18). To date,
it remains unclear if interventions that decrease plasma CRP
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concentrations ameliorate PTSD symptoms when administered
after the development of PTSD.
We also observed a significant impact of L. reuteri DSM
17938 on heart BPM during the TSST among Veterans with
PPC symptoms and PTSD. Increased heart BPM during the
TSST is a well-documented biomarker of the autonomic stress
response. In this study, the TSST induced increases in heart BPM
in participants who received placebo from ∼75 to 95 BPM, with
the peak response at the time of the math task. The results were
virtually identical to the response observed in a study of 260
healthy non-smoking males aged 16–60 years (59). Individuals
who had received daily supplementation with L. reuteri DSM
17938 responded with a significant reduction in the TSST-
induced increase in BPM, relative to individuals who received
placebo. Moreover, the observation that L. reuteri DSM 17938
had no effect on perceived stress suggests that the reduction in
the TSST-induced tachycardia was not secondary to a reduction
in perceived stress by the participants. Rather, L. reuteri DSM
17938 may alter autonomic output in a way that directly reduces
stress-induced sympathetic outflow.
In support of this hypothesis, a recent study found that
an 8-week administration of a fermented milk product with
probiotic (FMPP) among healthy women (60) reduced reactivity
in a widely distributed network of brain regions associated
with responses to a validated negatively valenced emotional face
attention task (60). Imaging data suggested a shift away from
an arousal-based resting-state network and toward a regulatory
network. The former network contained sensory regions
including thalamus and insula, limbic regions including cingulate
gyrus, amygdala, hippocampus, parahippocampal gyrus, the
basal ganglia, and attention-related regions (BA 40) consistent
with previous periaqueductal gray connectivity findings (61).
Functional studies have demonstrated that the periaqueductal
gray plays an important role in determining patterns of
autonomic activity associated with different forms of emotional
coping (62). Together, these data support the hypothesis that
anti-inflammatory/immunoregulatory probiotic interventions
alter patterns of autonomic activity responses during stress
exposure, potentially through a shift away from an arousal-based
resting-state network and toward a regulatory network.
Additionally, the use of L. reuteri DSM 17938 for 8 weeks did
not significantly alter the composition of the gut microbiome.
It is possible that alterations occurred in the participants’ gut
microbiomes that were not observed in the stool, as noted in
an 11-strain probiotic administration study of mice and humans
(63). Alternately, the use of L. reuteri DSM 17938 may have
induced a transient and individual-specific response that was
not detectable using the given sequencing technique (16S), or
findings could be confounded by the relatively small sample size.
In the present study, the probiotic was administered well after the
occurrence of the mTBI. In animal models, it has been observed
that the initial dysbiosis of the gut microbial community from
injury might be limited to days post-injury (64). Therefore, it is
possible that administration of a probiotic immediately following
injury could have a more dramatic observable and lasting
influence on gut microbiome composition. Findings associated
with the lack of changes observed in the gut microbiome
may also have been due to sampling procedures. Future trials
should include sampling mid-supplementation (e.g., 4 weeks) in
addition to post-supplementation.
LIMITATIONS
Like all other studies, this one had a number of limitations. Efforts
for this project were exploratory in nature, and one of the primary
goals was to evaluate feasibility, acceptability, and safety. By
intention, this initial study was not designed to evaluate changes
in symptoms associated with clinical conditions. As such, the
sample size was small, andmany physiological outcomemeasures
were obtained and analyzed. Funding was also limited, which
restricted the number of samples that could be analyzed. Ideally,
there would be at least one timepoint for all biological measures
while the participants were on the probiotic or placebo to assess
a longitudinal change.
CONCLUSIONS
Taken together, results support the submission of a large,
randomized, double blind, placebo-controlled trial focused
on mechanistic links between biological markers and clinical
outcomes, with the eventual goal of evaluating the efficacy of
L. reuteri DSM 17938 for decreasing PPC and PTSD symptoms.
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